Igc commences phase 1 of cannabinoid clinical trial for alzheimer's patients

Potomac, md--(business wire)-- #ad--india globalization capital, inc. (“igc” or the “company”) (nyse american: igc) announced that it is enrolling participants suffering from mild to severe dementia due to alzheimer's disease for its phase 1 clinical trial. our subsidiary, igc pharma, llc, received approval from an institutional review board (“irb”) as previously disclosed, engaged a principal investigator and a study site, and began enrolling participants for a phase 1 trial on its investigational d
IGC Ratings Summary
IGC Quant Ranking